GoodRx reshapes board after director exit
GoodRx Holdings, Inc. reported governance changes following a director departure.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
GoodRx Holdings, Inc. reported governance changes following a director departure. On March 31, 2026, Ian T. Clark resigned from the Board of Directors and the Nominating & Governance Committee, stating his decision was not due to any disagreement with the company or its management.
To rebalance director classes, the Board accepted Wendy Barnes’s resignation as a Class I director and immediately re-elected her as a Class III director. Her Board service is considered uninterrupted, and the Board now has three directors in each of Classes I, II, and III.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Ian T. Clark resignation date: March 31, 2026
Board class change decision date: April 2, 2026
Wendy Barnes reclassification effective: April 1, 2026
+1 more
4 metrics
Ian T. Clark resignation date
March 31, 2026
Effective date of director resignation
Board class change decision date
April 2, 2026
Date Board decided to move Wendy Barnes to Class III
Wendy Barnes reclassification effective
April 1, 2026
Date she resigned as Class I and was re-elected Class III
Directors per board class
3 directors per class
Board now has three directors in each of Classes I, II, III
Key Terms
Emerging growth company, Nominating & Governance Committee, Class I, Class III, +1 more
5 terms
Emerging growth company regulatory
"Emerging growth company Item 5.02 Departure of Directors"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Nominating & Governance Committee financial
"including his service on the Board’s Nominating & Governance Committee"
Class I financial
"move Wendy Barnes ... from Class I, with a term expiring at the 2027 annual meeting"
Class III financial
"to Class III, with a term expiring at the 2026 annual meeting"
Class III is the highest regulatory category for medical devices, covering products that support or sustain life, are implanted, or pose the greatest potential risk; these items must undergo extensive clinical testing and formal regulatory review before they can be sold. For investors, Class III status means longer timelines, higher development costs and greater approval risk, but successful clearance can yield strong market protection and sizable returns—like a product that needs a full road-test and inspection before it can be widely used.
annual meeting of stockholders financial
"with a term expiring at the 2027 annual meeting of stockholders"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What board change did GoodRx (GDRX) announce regarding Ian T. Clark?
GoodRx announced that Ian T. Clark resigned from its Board of Directors and the Nominating & Governance Committee effective March 31, 2026. He informed the company that his decision was not due to any disagreement over operations, policies, or practices.
Why did GoodRx (GDRX) rebalance its board classes after Clark’s resignation?
After Ian T. Clark’s resignation, GoodRx rebalanced its board classes to maintain an equal number of directors in each class. The Board adjusted director classifications so that Classes I, II, and III each consist of three directors following the change.
How did GoodRx (GDRX) change Wendy Barnes’s board classification?
GoodRx moved Wendy Barnes from a Class I director seat, with a term expiring at the 2027 annual meeting, to a Class III seat, with a term expiring at the 2026 annual meeting. This reclassification helped equalize the number of directors in each class.
Did Wendy Barnes leave the GoodRx (GDRX) board as part of this change?
Wendy Barnes tendered her resignation as a Class I director effective upon her election as a Class III director. The company states this resignation and immediate re‑election were solely to rebalance board classes, and her Board service is deemed uninterrupted.
How many directors does GoodRx (GDRX) now have in each board class?
GoodRx states that, after Ian T. Clark’s resignation and Wendy Barnes’s move to Class III, its Board of Directors now consists of three directors in Class I, three in Class II, and three in Class III, creating an equal balance among the classes.
Did Ian T. Clark cite any disagreements with GoodRx (GDRX) in his resignation?
Ian T. Clark informed GoodRx that his decision to resign from the Board and its Nominating & Governance Committee was not the result of any disagreement with the company or its management regarding operations, policies, or practices.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates